Advertisement


Yucai Wang, MD, PhD, on Richter Transformation of CLL: Findings on Combination Therapy With an Immune Checkpoint Inhibitor

2024 ASCO Annual Meeting

Advertisement

Yucai Wang, MD, PhD, of the Mayo Clinic, discusses the increased efficacy of combination therapy with pembrolizumab plus a BCR kinase inhibitor compared with pembrolizumab alone in patients with Richter transformation of chronic lymphocytic leukemia (CLL; Abstract 7050).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
So, Richter's transformation is a rare but devastating complication of chronic lymphocytic leukemia or small lymphocytic lymphoma. The prognosis of this disease is poor without established standard of care treatments. Our institution did a phase two clinical trial investigating the efficacy of pembrolizumab in this disease. Previously, we have reported preliminary efficacy results of this trial. So in the first nine patients with Richter's transformation, we observed a response rate of 44%. In this updated analysis, we report updated efficacy data of single-agent pembrolizumab and the combination therapy with pembrolizumab and a BCR inhibitor. So in this trial, patients were first treated with single-agent pembrolizumab every three weeks for up to 12 months. Patients who only have stable disease after three cycles of treatment or those who progress at any time during this single-agent treatment phase can add a inhibitor of the B-cell receptor, either with a BTK inhibitor or a PI3K inhibitor. So in this updated analysis, we enrolled a total of 26 patients, nine in the initial cohort, as reported a number of years earlier, and 17 in an expansion cohort. Looking at the patient and the disease baseline characteristics, this is consistent with what you would observe in this patient population. To highlight, most of the patients had unmutated IgHV and about 40% of the patients had TP53 alterations. This is a heavily pretreated population with a median of three lines of prior therapy, with up to 11 lines of therapy for CIL and five lines of therapy for Richter's transformation. Over half of the patients were previously exposed to BTK inhibitor ibrutinib already, and the massive majority of those patients actually had disease progression on this agent. So again, a high-risk patient population, difficult to treat. So in this trial, we observed that with single-agent pembrolizumab treatment, the objective response rate was 23%, or six out of 26 responses. It was two CR and 4 PRs. What's interesting is that for the 16 patients who went on to receive a doublet therapy with pembrolizumab either in combination with ibrutinib or idelalisib, we saw a high response rate of over 60%. So again, these are patients who progressed through pembrolizumab, and most of the patients have been previously exposed to ibrutinib, so this 60% response rate is very encouraging. In terms of survival outcomes, in a single-agent phase they observed the median progression-free survival was three months, and the median progression-free survival in the doublet therapy phase was about eight months. In total, the median overall survival is about one year, and the overall survival rate at two years is 27%. So again, in this heavily pretreated population with high-risk disease features, this doublet therapy certainly looks very encouraging in inducing a response and to maintain that. So these data do suggest that a PD-L1 blockade in combination with a BCR inhibitor is efficacious in treating Richter's transformation and it warrants further exploration. We do have another ongoing trial examining the combination of PD-L1 blockade in combination with a BTK inhibitor and the venetoclax in this patient population, and we look forward to sharing those results in the future.

Related Videos

Leukemia
Lymphoma

William G. Wierda, MD, PhD, on CLL/SLL: Updated Findings on Ibrutinib and Venetoclax

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses up to 5.5 years of follow-up data from the phase II CAPTIVATE study, showing that in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), fixed duration ibrutinib plus venetoclax continues to provide clinically meaningful progression-free disease in those with high-risk genomic features as well as in the overall population (Abstract 7009).

Lymphoma

Yasmin H. Karimi, MD, on Large B-Cell Lymphoma: Follow-up on Subcutaneous Epcoritamab Monotherapy

Yasmin H. Karimi, MD, of the University of Michigan Comprehensive Cancer Center, discusses 2.5-year follow-up data on epcoritamab monotherapy for patients with relapsed or refractory large B-cell lymphoma. The subcutaneous regimen continues to demonstrate durable responses (Abstract 7039).

Multiple Myeloma

Luciano J. Costa, MD, PhD, on Multiple Myeloma: Subgroup Analysis of CARTITUDE-4 on Ciltacabtagene Autoleucel

Luciano J. Costa, MD, PhD, of the University of Alabama at Birmingham, discusses recent findings from the CARTITUDE-4 trial showing that, in patients with lenalidomide-refractory functional high-risk multiple myeloma after one prior line of treatment, ciltacabtagene autoleucel improved outcomes vs the standard of care (Abstract 7504).

Multiple Myeloma

Suzanne Trudel, MD, on Multiple Myeloma: Results From the DREAMM-8 Study of Treatments After Relapse

Suzanne Trudel, MD, of Canada’s Princess Margaret Cancer Centre, discusses phase III findings showing that, in patients with relapsed or refractory multiple myeloma who had one or more prior lines of treatment, belantamab mafodotin-blmf plus pomalidomide and dexamethasone improved progression-free survival and showed a favorable overall survival trend compared with pomalidomide plus bortezomib and dexamethasone.

Lymphoma

Peter Riedell, MD, on DLBCL: Expert Commentary on Data From the ECHELON-3 Study

Peter Riedell, MD, of The University of Chicago, discusses phase III findings on the regimen of brentuximab vedotin in combination with lenalidomide and rituximab for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This therapy demonstrated a survival advantage in the third-line setting, but as this is an interim analysis, questions remain regarding long-term safety and duration of response, according to Dr. Riedell (Abstract LBA7005).

Advertisement

Advertisement




Advertisement